AstraZeneca released the full tozorakimab COPD trial results on 8 September 2026. The company presented them as a late breaker at the European Respiratory Society Congress in Barcelona. The slot was the ALERT-2 plenary session. The New England Journal of Medicine published the trials the same day. The topline had already been announced in March 2026. What arrived this week was the detail underneath it.
That detail carries unusual weight. A rival programme against the same cytokine has already shown how narrow this pathway can be. The target is interleukin 33, and the disease is chronic obstructive pulmonary disease. For commissioners, payers and respiratory clinicians, the question is not whether the drug works. It is who it works for, and whether that group sits inside the pathway the NHS already funds.
What the OBERON and TITANIA trials reported
OBERON and TITANIA are replicate Phase III trials in symptomatic COPD. Together they randomised 2,306 patients. Each participant received tozorakimab 300mg by subcutaneous injection every four weeks, or placebo. Treatment was added to inhaled standard of care and ran for 52 weeks. Entry required at least two moderate or one severe exacerbation in the previous 12 months.
The primary endpoint was the annualised rate of moderate to severe exacerbations in former smokers. AstraZeneca reported a 29 per cent reduction in OBERON (rate ratio 0.71, 95 per cent CI 0.57 to 0.88). TITANIA showed 34 per cent (rate ratio 0.66, 95 per cent CI 0.55 to 0.80). Both trials met that endpoint.
The key secondary endpoint covered the overall population of current and former smokers. OBERON reported a 30 per cent reduction there (rate ratio 0.70, 95 per cent CI 0.58 to 0.85). TITANIA reported 29 per cent (rate ratio 0.71, 95 per cent CI 0.59 to 0.84). The effect therefore held once current smokers were included.
The 43 per cent figure is a subgroup result
Several outlets led on a 43 per cent reduction. That number comes from a pooled analysis of patients with blood eosinophils at or above 300 cells per microlitre. The rate ratio was 0.57 (95 per cent CI 0.44 to 0.74). It is not the primary endpoint of either trial. The pooled figure at or above 150 cells was 34 per cent. The rate ratio there was 0.66 (95 per cent CI 0.56 to 0.78). Below 150 cells the reduction was 23 per cent (rate ratio 0.77, 95 per cent CI 0.62 to 0.94).
That last number is the commercially interesting one, because no COPD biologic currently reaches those patients in the UK. It is also the smallest of the three.
Why former smokers defined the primary tozorakimab COPD trial population
The design choice was not arbitrary. Sanofi and Regeneron ran two Phase III trials of itepekimab, another antibody against interleukin 33, in COPD. Both AERIFY-1 and AERIFY-2 enrolled former smokers only, defined as not having smoked for at least six months. AERIFY-1 met its primary endpoint with a 27 per cent reduction in exacerbations at week 52. AERIFY-2 missed, at 2 per cent and 12 per cent on its two dosing arms.
AstraZeneca kept former smokers as the primary analysis population, then enrolled current smokers as well. The published design of the Phase III LUNA programme offers a mechanistic reason. Airway expression of interleukin 33 is raised in severe COPD, and particularly so in former smokers.
The practical effect is a programme that hedged against the itepekimab outcome and still read out in the broader group. LSDN notes that the reverse reading is also available. A primary endpoint set in the narrower population is a lower bar than one set across the whole enrolled cohort.
Cytokine directed biologics have had a difficult run in large outcome trials this year. Novo Nordisk stopped two Phase 3 studies of the interleukin 6 antibody ziltivekimab last week. The decision was made on futility grounds, as LSDN reported on 7 September. That context is part of why two replicate wins in COPD registered as strongly as they did.
What the companies and investigators said
Frank Sciurba is Professor of Pulmonary and Critical Care Medicine at the University of Pittsburgh. He is chief investigator of the LUNA programme. In the company release he called the finding a first. The trials “mark the first time we have seen a biologic in COPD achieve efficacy”, he said. That efficacy came “in a broad population across blood eosinophil thresholds”. He added that this included “patients with baseline eosinophils below 150, and irrespective of smoking status”. That is an investigator statement carried in a sponsor announcement, and LSDN reports it as such.
Sharon Barr is Executive Vice President, BioPharmaceuticals R&D at AstraZeneca. She said the results “set a new standard for COPD treatment outcomes”. That standard applies “in a broad population of patients”. She said the company had “clinically validated the novel approach of targeting the signalling of the two forms of IL-33”. AstraZeneca describes tozorakimab as first in class. It says the antibody inhibits both the reduced and the oxidised forms of the cytokine. Dupilumab acts on the interleukin 4 and 13 pathway. Mepolizumab targets interleukin 5.
The safety statement runs to a single sentence
AstraZeneca described tolerability in one line. Tozorakimab was “generally well tolerated with a favourable safety profile”, the company said. It added that “the only adverse drug reaction was injection-site reaction”. The release reports no serious adverse event rates, no deaths and no discontinuation figures for either trial. LSDN found none in the company statement as at 9 September 2026. The journal safety tables sit behind the publisher paywall and were not obtained.
A peer reviewed pooled safety analysis of the earlier FRONTIER Phase 2 programme gives more. It covers 1,076 participants, 738 on tozorakimab and 338 on placebo, across four studies. FRONTIER-4 was the COPD and chronic bronchitis study. Serious treatment emergent adverse events reached 20.9 per cent on tozorakimab. The placebo figure was 13.2 per cent. The authors described most of these events as disease related.
Injection site reactions ran at 1.2 to 20.9 per cent on tozorakimab across those four studies. The placebo range was 0.0 to 4.9 per cent. Deaths were reported only in FRONTIER-1, at 0.9 per cent and 0.8 per cent. None was attributed to the drug. That is an earlier dataset, in different diseases and across a range of doses. It is not the Phase III safety record, and LSDN does not present it as one.
What a single safety line does not tell a formulary committee
Payers assessing a chronic maintenance biologic need discontinuation rates and serious event rates by arm. Neither appears in the announcement. The company release is a commercial document rather than a safety record. The fuller picture will come from the label and the journal report.
What it would mean for UK access
Around 1.7 million people in the UK have diagnosed COPD, on Asthma + Lung UK figures. The charity estimates a further 600,000 are undiagnosed. Only a small share of that population currently reaches a biologic at all.
NICE recommends dupilumab as an add on maintenance treatment for uncontrolled COPD with raised blood eosinophils. Uncontrolled means one or more severe exacerbations in the previous 12 months. Two or more moderate exacerbations also qualify. Patients must be on triple therapy. Dual therapy counts where an inhaled corticosteroid is unsuitable. NHS England has issued business case guidance for COPD biologics. Initiation sits with a respiratory specialist, with reviews at six and twelve months. A mepolizumab appraisal was still in progress when that guidance was published.
The eosinophil count is the gate. The tozorakimab COPD trial data report a benefit below 150 cells per microlitre. That sits on the far side of the gate. Should that survive regulatory review, the eligible pool widens well beyond the group the current pathway was built for. LSDN frames this as an observation about the pathway, not as a NICE position on tozorakimab.
Regulatory position, and the missing UK line
The FDA has accepted the biologics licence application for Priority Review. AstraZeneca anticipates a Prescription Drug User Fee Act date in the first quarter of 2027. That follows use of a priority review voucher. The company says tozorakimab is under regulatory review in major markets including the EU and China.
The release names no UK submission. LSDN found no MHRA filing announcement for tozorakimab in COPD as at 9 September 2026. That is a dated search finding and not a statement about the company plans. AstraZeneca has been active with regulators this month. It secured US accelerated approval for camizestrant on 4 September.
What the record still does not settle
The two trials ran for 52 weeks. Durability beyond that sits with PROSPERO, the long term extension for OBERON and TITANIA completers. MIRANDA tested a two weekly dose and met its primary endpoint. AstraZeneca announced that result on 20 April 2026 and disclosed no percentage reductions. The four studies carry the registration numbers NCT05166889, NCT05158387, NCT06040086 and NCT05742802.
The programme leaves several commercial questions open. No head to head study against dupilumab or mepolizumab exists. The eosinophil figures are pooled subgroup analyses rather than powered endpoints. No price has been disclosed in any market. Market reaction to the 8 September publication is not cleanly readable. Outlets differed on the direction of the share move that day. LSDN therefore reports no figure.
For a trade audience the practical question is narrow. COPD biologic access in the UK is currently defined by a blood test. A drug with data on both sides of that threshold changes what the pathway has to decide. It also changes how much of that pathway has to be funded.
